ImmunoGen Presents Preclinical Data on IMGC936 at the AACR Virtual Annual Meeting
April 10 2021 - 8:30AM
Business Wire
First-in-Class ADAM9-Targeting ADC Demonstrates Anti-Tumor
Activity in Multiple Solid Tumor Models
ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field
of antibody-drug conjugates (ADCs) for the treatment of cancer,
today announced that a poster highlighting preclinical data for its
novel ADAM9-targeting ADC, IMGC936, which is being investigated in
multiple solid tumor types, is being presented at the American
Association of Cancer Research (AACR) Virtual Annual Meeting April
10-15, 2021.
“ADAM9 is overexpressed in a wide range of solid tumors and
minimally expressed on normal tissue, which makes it an ideal ADC
target,” said Eric Westin, MD, Vice President, Clinical Development
and Translational Sciences at ImmunoGen. “IMGC936 showed compelling
anti-tumor activity against multiple patient-derived xenograft
models with clinically relevant levels of ADAM9 and was
well-tolerated across all models tested. We continue to enroll
patients in our Phase 1 dose-escalation study of IMGC936 in
multiple tumor types and look forward to sharing initial data by
the end of 2021 or early 2022.”
POSTER PRESENTATION
- Title: “IMGC936, an investigational ADAM9-targeting
antibody-drug conjugate, is active against patient-derived
ADAM9-expressing xenograft models”
- Day/Time: Saturday, April 10, 2021 at 8:30 AM ET
- Session Category: Immunology
- Session Title: PO.IM02.10 - Therapeutic Antibodies,
Including Engineered Antibodies
- Abstract: 1841
Additional information can be found at www.aacr.org.
ABOUT IMGC936 IMGC936 is a first-in-class ADAM9-targeting
antibody-drug conjugate (ADC) that is comprised of a humanized
antibody engineered to include a YTE mutation for enhanced exposure
through improved recycling, a tri-peptide cleavable linker stable
in circulation, and a next-generation DM21 maytansinoid payload,
which is more potent and hydrophobic, resulting in increased
bystander activity.
ADAM9 is a cell surface protein that belongs to the ADAM (a
disintegrin and metalloproteinase) family of proteases, which have
been implicated in cytokine and growth factor shedding and cell
migration. Dysregulation of ADAM9 has been involved in tumor
progression and metastasis, as well as pathological
neovascularization. ADAM9 is overexpressed in multiple solid tumor
types (e.g., non-small cell lung, gastric, pancreatic,
triple-negative breast, and colorectal cancers) and minimally
expressed on normal tissue, making ADAM9 an attractive target for
ADC development.
IMGC936 is being co-developed with MacroGenics and is currently
in a Phase 1 study enrolling patients with solid tumors that
express ADAM9.
ABOUT IMMUNOGEN ImmunoGen is developing the next
generation of antibody-drug conjugates (ADCs) to improve outcomes
for cancer patients. By generating targeted therapies with enhanced
anti-tumor activity and favorable tolerability profiles, we aim to
disrupt the progression of cancer and offer our patients more good
days. We call this our commitment to TARGET A BETTER NOW™.
Learn more about who we are, what we do, and how we do it at
www.immunogen.com.
FORWARD-LOOKING STATEMENTS This press release includes
forward-looking statements based on management's current
expectations. These statements include, but are not limited to,
ImmunoGen’s expectations related to: the occurrence, timing, and
outcome of potential preclinical, clinical, and regulatory events
related to the Company’s product candidates; and the presentation
of preclinical and clinical data on the Company’s product
candidates. For these statements, ImmunoGen claims the protection
of the safe harbor for forward-looking statements provided by the
Private Securities Litigation Reform Act of 1995. Various factors
could cause ImmunoGen’s actual results to differ materially from
those discussed or implied in the forward-looking statements, and
you are cautioned not to place undue reliance on these
forward-looking statements, which are current only as of the date
of this release. Factors that could cause future results to differ
materially from such expectations include, but are not limited to:
the timing and outcome of the Company’s preclinical and clinical
development processes; the difficulties inherent in the development
of novel pharmaceuticals, including uncertainties as to the timing,
expense, and results of preclinical studies, clinical trials, and
regulatory processes; the Company’s ability to financially support
its product programs; risks and uncertainties associated with the
scale and duration of the COVID-19 pandemic and the resulting
impact on ImmunoGen’s industry and business; and other factors as
set forth in the Company’s Annual Report on Form 10-K filed with
the Securities and Exchange Commission on March 1, 2021, and other
reports filed with the Securities and Exchange Commission.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210410005010/en/
INVESTOR RELATIONS AND MEDIA CONTACTS ImmunoGen Courtney
O’Konek 781-895-0600 courtney.okonek@immunogen.com
OR
FTI Consulting Robert Stanislaro 212-850-5657
robert.stanislaro@fticonsulting.com
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Apr 2023 to Apr 2024